Aurobindo Pharma, Intas submit bids for $1 billion buyout of Teva: Report

29 Aug 2016 Evaluate

Aurobindo Pharma and Intas are reportedly among the final contenders for the UK and Irish portfolio of Israeli generics behemoth Teva, put up for sale to comply with European anti-trust regulations. Both the entities have submitted their binding offers of around $1 billion along with firm financing commitments.

Teva is selling assets as part of a broader divestiture process to comply with the anti-trust regulations for its $40.5 billion acquisition of Allergan Plc’s generics business that was announced last year.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1224.75 14.85 (1.23%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×